OakChart

Adagio Medical Holdings Inc

ADGMHealthcare·Medical Devices·USA·Nano·NASD·Nov 11 • 9:18 AM ET

1.74-0.10 (-5.43%)
2026-11-11 15:22 CET
Market cap
1.68 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-27.14 USD m
Free cash flow, TTM
-16.57 USD m
EPS diluted, TTM
-43.18
P/E
-
Compare

Price

ADGM against its 20, 50 and 200-day averages
2050200missearnings
0.0010.0020.0030.007.9M15.9MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ADGMclose 1.7420-day 2.7250-day 6.98200-day 21.491.74

96.6% under 50.70 on 15 Apr 2026. Last 15 sessions, 130.0% high to low

Profile

ADGM
52-week range, 0% of the way up
1.5050.70

Adagio Medical Holdings, Inc. is a medical device company, which engages in the development ablation technologies for the treatment of cardiac arrhythmias. It treats atrial fibrillation, atrial flutter, and ventricular tachycardia. The company was founded on August 24, 2020 and is headquartered in Laguna Hills, CA.

Employees41
IPOFeb 26, 2021
Beta0.10
ATR, 14d0.62
Rel volume1.01
Short float0.58%
Insider own1.22%

Snapshot

6 groups

Valuation

Index-
Market Cap1.59M
Enterprise Value19.85M
Income-27.14M
Sales0.00M
Book/sh-0.56
Cash/sh8.48
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees41
IPOFeb 26, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B-
P/C0.21
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio1.15
Current Ratio1.41
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-43.18
EPS next Y-34.80
EPS next Q-7.40
EPS this Y27.81%
EPS next Y-6.42%
EPS next 5Y4.30%
EPS past 3/5Y63.65% -363.15%
Sales past 3/5Y- -
EPS Y/Y TTM70.33%
Sales Y/Y TTM-100.00%
EPS Q/Q13.44%
Sales Q/Q-
EarningsAug 11 BMO
EPS/Sales Surpr.-11.11% -

Ownership

Insider Own1.22%
Insider Trans0.00%
Inst Own-
Inst Trans-2.44%
ROA-77.80%
ROE-657.76%
ROIC-107.02%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-35.98%
SMA50-75.07%
SMA200-91.90%
Trades-

Technical

Shs Outstand0.91M
Shs Float0.90M
Short Float0.58%
Short Ratio0.06
Short Interest0.01M
52W High50.70 -96.57%
52W Low1.50 16.00%
Volatility24.06% 19.65%
ATR (14)0.62
RSI (14)23.96
Beta0.10
Rel Volume1.01
Avg Volume83.43K
Volume4,214

Performance

Perf Week-32.71%
Perf Month-53.71%
Perf Quarter-91.59%
Perf Half Y-93.56%
Perf YTD-94.42%
Perf Year-93.35%
Perf 3Y-99.47%
Perf 5Y-99.42%
Perf 10Y-
Recom1.00
Target Price100.00
Prev Close1.84
Price1.74
Change %-5.43%

Analyst ratings

latest 2 of 2
DateActionAnalystRating changeTargetImplied
Apr 14, 2026InitiatedPPiper SandlerOverweight$3+72.4%
Dec 02, 2025InitiatedLLake StreetBuy$4+129.9%

Peers

Mkt cap
TickerCompanyMkt cap
BSXBoston Scientific Corp64.05B
MDTMedtronic Plc128.68B
ABTAbbott Laboratories189.30B
ICCMIcecure Medical Ltd2.74M
ATRCAtricure Inc2.86B
STXSStereotaxis Inc84.17M
AMIXAutonomix Medical Inc3.37M
NUWENuwellis Inc2.77M
NSPRInspireMD Inc36.72M
CVRXCVRx Inc19.94M

Insider trading

2 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Kaster DeborahChief Financial OfficerDec 16 '25Buy1.2015,00017,97315,000Dec 18 06:00 AM
Usen ToddChief Executive OfficerDec 12 '25Buy1.09207,315225,973207,315Dec 15 09:24 PM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B

News

latest 14 of 98
  • Adagio Medical Provides Business Update: 22 Patients Treated with Next-Generation vCLAS Ultra System as FULCRUM-VT IDE Sub-Study Advances (Business Wire)
  • Adagio Medical Initiates Strategic Review and Workforce Reduction While Advancing vCLAS PMA (InvestorsHub) -53.04%
  • Adagio Medical Announces Strategic Review Process to Maximize Shareholder Value (Business Wire)
  • Adagio Medical Highlights First Patient Treated in IDE Study Evaluating Next-Generation vCLAS Ultra System for Ventricular Tachycardia at Banner - University Medical Center Phoenix (Business Wire) +7.99%
  • Teleflex Appoints Veteran Medical Technology Executive Sean M. Salmon to Teleflex Board of Directors (Business Wire) +7.71%
  • Loading…
  • Adagio Medical Reports Second Quarter 2026 Results (Business Wire)
  • Adagio Medical Treats First Patient with Faster, Single-Freeze Next-Generation ULTA System (Business Wire) +21.60%
  • Adagio Medical Submits Premarket Approval Application to FDA for vCLAS Ventricular Ablation System for the Treatment of Ventricular Tachycardia (Business Wire)
  • Adagio Medical Reports First Quarter 2026 Results and Meaningful Clinical Progress (Business Wire)
  • Adagio Medical to Participate in the BofA Securities 2026 Health Care Conference (Business Wire)
  • Adagio Medical Announces Positive Pivotal Results for vCLAS Ventricular Ablation System (Business Wire)
  • Adagio Medicals ULTA Technology to Be Featured at the Heart Rhythm 2026 Conference (Business Wire)
  • Adagio Medical to Participate in the 25th Annual Needham Virtual Conference (Business Wire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-11-9.000-8.100-9.0000.000.002
2026Q12026-05-12-9.300-8.700-9.4480.000.002
2025Q42026-03-27-6.300-9.300-4.9240.000.001
2025Q32025-12-03-12.900-12.900-19.7340.000.001
2025Q22025-08-13---10.481---
2025Q12025-05-15---15.049---
2024Q42025-04-02---3.7750.14--
2024Q32024-11-14---0.3190.19--
2026Q3---7.400--0.003
2026Q4---7.800--0.003
2027Q1---7.350--0.202
2027Q2---7.950--0.302
2027Q3---8.700--0.502
2027Q4---10.200--0.902
2028Q1---4.200--1.001
2028Q2---2.700--1.701

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2025FY-45.300-50.100-45.3000.000.00
2026FY--32.700--0.00
2027FY--34.800--1.53
2028FY--39.700--7.26
2029FY--74.700--20.31
2030FY--78.600--42.85

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-113000.000.000.00
2026Q3S2026-08-022000.000.000.00
2026Q3S2026-06-023000.000.000.00
2026Q3S2026-05-122000.000.000.00
2026Q3S2026-04-132000.000.000.00
2026Q3S2026-03-271000.000.000.00
2026Q3S2025-12-031000.000.000.00
2026Q3S2025-12-011000.000.000.00
2026Q3R2026-08-11100-4.80-4.80-4.80
2026Q3R2026-06-02100-4.80-4.80-4.80
2026Q3E2026-10-25300-7.40-9.00-4.80
2026Q3E2026-08-11310-7.40-9.00-4.80
2026Q3E2026-08-02200-6.60-8.40-4.80
2026Q3E2026-07-26300-8.40-12.00-4.80

Estimate history

EPS, annual-0.001-0.342-31.498-0.218-4.938-45.395-43.1787
Period202020212022202320242025TTM
EPS, quarterly-6.441-0.319-3.775-15.049-10.481-19.734-4.924-9.448-9.073
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual000.18900.60200
Period202020212022202320242025TTM
Sales, quarterly0.2540.1850.137000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual19.18719.1870.7567.92715.1980.740.74
Period202020212022202320242025MRQ
Shares, quarterly0.7814.53515.1980.5130.5130.5130.740.740.74
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Total Revenue0.000.000.600.000.190.000.00
Cost of Goods Sold Incl. D&A1.241.653.320.001.370.000.00
Gross Profit-1.24-1.65-2.720.00-1.180.000.00
Selling, General and Administrative Excl. Other18.5920.2432.244.7522.736.610.01
Research and Development9.1710.6412.22-17.36--
Other Operating Expense0.000.000.000.000.000.000.00
Operating Income-19.82-21.89-34.96-4.75-23.91-6.61-0.01
Interest Expense3.112.912.92-0.14-0.00
Unusual Expense4.650.9639.450.000.00-0.050.00
Net Income Before Taxes-27.14-25.08-75.04-2.13-23.67-6.56-0.01
Income Taxes0.000.000.000.000.000.000.00
Consolidated Net Income-27.14-25.08-75.04-2.13-23.67-6.56-0.01
Net Income From Continuing Operations-27.14-25.08-75.04-2.13-23.67-6.56-0.01
Net Income-27.14-25.08-75.04-2.13-23.67-6.56-0.01
EPS (Recurring)-32.26-44.18-3.12-0.22-31.50-0.34-0.00
EPS (Basic, Before Extraordinaries)-43.18-45.40-4.94-0.22-31.50-0.34-0.00
EPS (Diluted)-43.18-45.40-4.94-0.22-31.50-0.34-0.00
EBITDA-18.68-20.92-33.57-4.75-23.42-6.61-0.01
Non-Operating Income (Expense)0.440.672.292.620.380.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.00
Stock Option Compensation Expense1.901.480.64-0.36--
Price To Sales Ratio--26.51-40.16--
Gross Margin---451.16--624.87--
Operating Margin---5,806.98--12,652.38--
Net Margin---12,465.28--12,525.40--
Shares Outstanding0.740.7415.207.930.7619.1919.19
Market Capitalization1.681.68478.74444.78---

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.140.18
Cost of Goods Sold Incl. D&A0.200.210.290.530.340.391.520.57
Gross Profit-0.20-0.21-0.29-0.53-0.34-0.39-1.39-0.39
Selling, General and Administrative Excl. Other4.734.993.675.194.387.017.4710.24
Research and Development2.252.532.122.271.973.663.422.47
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-4.93-5.20-3.97-5.72-4.72-7.40-8.85-10.63
Interest Expense0.810.780.780.750.720.660.670.74
Unusual Expense0.981.19-1.263.74-1.29-0.2349.92-6.50
Net Income Before Taxes-6.72-7.00-3.31-10.12-3.95-7.71-57.37-4.63
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-6.72-7.00-3.31-10.12-3.95-7.71-57.37-4.63
Net Income From Continuing Operations-6.72-7.00-3.31-10.12-3.95-7.71-57.37-4.63
Net Income-6.72-7.00-3.31-10.12-3.95-7.71-57.37-4.63
EPS (Recurring)-8.15-8.32-6.24-14.63-12.24-15.36-1.48-0.63
EPS (Basic, Before Extraordinaries)-9.07-9.45-4.92-19.73-7.70-15.05-3.77-0.32
EPS (Diluted)-9.07-9.45-4.92-19.73-10.48-15.05-3.77-0.32
EBITDA-4.73-4.99-3.73-5.22-4.45-7.13-8.43-10.38
Non-Operating Income (Expense)0.000.180.170.090.200.122.080.24
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.480.390.890.140.230.22--
Price To Sales Ratio---217.8162.1021.4927.7185.42
Gross Margin-------1,011.68-208.65
Operating Margin-------6,462.04-5,746.49
Net Margin-------41,875.18-2,502.16
Shares Outstanding0.740.740.740.510.510.5115.2014.54
Market Capitalization1.6825.5423.1029.8420.0012.38478.741,125.02

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY
Cash & Short Term Investments17.1120.590.025.550.500.00
Short Term Receivables0.000.040.000.000.000.00
Inventories1.672.570.000.370.000.00
Other Current Assets1.302.160.060.820.370.00
Total Current Assets20.0825.350.086.730.870.00
Net Property, Plant & Equipment2.232.150.001.940.000.00
Total Investments and Advances0.000.0040.580.00149.550.00
Intangible Assets20.9420.940.000.000.000.00
Deferred Tax Assets1.981.75----
Other Assets0.000.010.000.030.000.04
Total Assets45.2350.2040.658.70150.420.04
Short Term Debt Incl. Current Port. of LT Debt0.150.142.179.660.000.00
Accounts Payable1.082.840.001.010.000.00
Other Current Liabilities7.004.7810.182.295.990.06
Total Current Liabilities8.237.7612.3512.975.990.06
Long Term Debt21.6016.120.0091.600.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities2.862.63----
Other Liabilities0.133.772.620.005.230.00
Total Liabilities32.8330.2814.97104.5711.220.06
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity12.4019.9125.68-95.88139.20-0.01
Total Shareholders Equity12.4019.9125.68-95.88139.20-0.01
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity12.4019.9125.68-95.88139.20-0.01
Total Liabilities & Stockholders Equity45.2350.2040.658.70150.420.04
Book Value Per Share16.751.313.24-126.797.26-0.00
Tangible Book Value Per Share-11.53-0.073.24-126.797.26-0.00
Full-Time Employees418033--
Price to Book Ratio-3.2824.045.81---
Return on Assets-52.57-165.20-2.22-29.76-8.72-
Return on Equity-155.25-329.16-2.53-109.27-9.43-
Return on Invested Capital-73.77-208.25-8.31--4.71-
Quick Ratio2.242.930.010.490.150.03
Current Ratio2.443.270.010.520.150.03

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Net Income-27.14-25.08-75.04-2.13-23.67-6.56-0.01
Depreciation0.840.971.39-0.49--
Other Funds (Non Cash)6.542.4440.33-2.620.44-0.050.01
Funds from Operations-19.75-21.68-35.25-4.75-22.74-6.61-0.00
Extraordinary Item0.000.000.000.000.000.000.00
Changes in Working Capital3.222.665.794.030.335.540.00
Cash from Operating Activities-16.53-19.01-29.46-0.73-22.41-1.070.00
Capital Expenditures-0.04-0.37-1.650.00-0.500.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.00-1.400.00-149.500.00
Purchase of Investments0.000.000.00-1.400.00-149.500.00
Sale Or Maturity of Investments0.000.000.000.000.00-0.00
Other Uses0.000.000.000.000.000.000.00
Other Sources0.000.000.00115.070.000.000.00
Cash from Investing Activities-0.04-0.37-1.65113.67-0.50-149.500.00
Cash Dividends Paid0.000.000.000.000.000.000.00
Change in Capital Stock16.1316.130.00-115.070.03151.110.00
Repurchase of Common Pref Stock0.000.000.00-115.070.000.000.00
Sale of Common Pref Stock16.1316.130.000.000.03151.110.00
Proceedsfrom Stock Options0.000.000.000.000.00151.110.00
Issuance or Reduction of Debt, Net0.000.0015.632.069.50-0.030.00
Change in Long Term Debt0.000.0015.632.069.50-0.030.00
Issuance of Long Term Debt0.000.0016.502.069.500.130.00
Reduction of Long Term Debt0.000.00-0.870.000.00-0.160.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.00
Cash from Financing Activities16.1316.1315.63-113.029.53151.070.00
Exchange Rate Effect-0.02-0.230.20-0.08--
Net Change in Cash-0.46-3.48-15.27-0.07-13.310.500.00
Free Cash Flow-16.57-19.39-31.11-0.73-22.90-1.070.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.00-1.920.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments7.7412.9117.114.678.2012.96
Short Term Receivables0.000.000.000.000.000.00
Inventories1.991.601.671.551.842.31
Other Current Assets0.961.341.301.922.192.10
Total Current Assets10.6915.8620.088.1412.2317.37
Net Property, Plant & Equipment2.262.522.232.462.703.02
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets20.9420.9420.9420.9420.9420.94
Deferred Tax Assets--1.98---
Other Assets0.000.000.000.010.010.01
Total Assets33.8839.3145.2331.5535.8841.34
Short Term Debt Incl. Current Port. of LT Debt0.230.230.150.180.200.26
Accounts Payable0.701.221.081.021.312.65
Other Current Liabilities6.637.137.008.503.363.10
Total Current Liabilities7.568.578.239.704.886.01
Long Term Debt25.7723.8621.6021.7917.5718.32
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities0.880.882.860.880.880.88
Other Liabilities0.080.260.130.493.873.73
Total Liabilities34.3033.5832.8332.8627.2128.94
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-0.415.7212.40-1.318.6712.40
Total Shareholders Equity-0.415.7212.40-1.318.6712.40
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-0.415.7212.40-1.318.6712.40
Total Liabilities & Stockholders Equity33.8839.3145.2331.5535.8841.34
Book Value Per Share-0.567.7316.75-2.5616.9024.18
Tangible Book Value Per Share-28.84-20.55-11.53-43.39-23.93-16.65
Full-Time Employees--41---
Price to Book Ratio-3.284.461.86-22.742.311.00
Return on Assets-77.80-60.43-52.57-114.09-335.23-190.17
Return on Equity-657.76-268.88-155.25-210.36--428.31
Return on Invested Capital-26.49-23.64-9.72-49.42-15.04-25.11
Quick Ratio1.151.662.240.682.132.51
Current Ratio1.411.852.440.842.502.89

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-6.72-7.00-3.31-10.12-3.95-7.71
Depreciation0.200.210.240.190.270.27
Other Funds (Non Cash)1.461.58-0.884.38-1.05-0.01
Funds from Operations-5.06-5.20-3.95-5.54-4.73-7.45
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.201.07-0.192.540.070.24
Cash from Operating Activities-5.26-4.13-4.14-3.01-4.66-7.21
Capital Expenditures-0.01-0.000.49-0.52-0.01-0.34
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.01-0.000.49-0.52-0.01-0.34
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.0016.130.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.0016.130.000.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.000.0016.130.000.000.00
Exchange Rate Effect0.10-0.07-0.060.00-0.10-0.08
Net Change in Cash-5.17-4.2012.43-3.53-4.76-7.62
Free Cash Flow-5.27-4.13-3.65-3.53-4.67-7.55

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.57%0.0M0.9M318.22K
2026-10-150.49%0.0M0.9M313.66K
2026-09-305.90%0.0M0.7M294.54K
2026-09-151.89%0.0M0.7M272.83K
2026-08-311.19%0.0M0.7M268.17K
2026-08-141.49%0.0M0.7M271.38K
2026-07-310.27%0.0M0.7M3.04K
2026-07-150.29%0.0M0.7M3.38K
2026-06-300.28%0.0M0.7M4.66K
2026-06-150.32%0.0M0.7M4.64K
2026-05-290.29%0.0M0.7M4.43K
2026-05-150.19%0.0M0.7M3.70K
2026-04-300.29%0.0M0.7M3.74K
2026-04-150.23%0.0M0.7M3.26K
2026-03-310.11%0.0M0.7M2.40K
2026-03-130.07%0.0M0.7M4.38K
2026-02-270.36%0.0M0.7M5.06K
2026-02-130.36%0.0M0.7M5.40K
2026-01-300.27%0.0M0.7M5.43K
2026-01-150.28%0.0M0.7M5.68K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-11-10SEC
2026-11-058-KCurrent report2026-11-04SEC
2026-10-268-KCurrent report2026-10-23SEC
2026-10-134Statement of changes in beneficial ownership of securities2024-09-27SEC
2026-10-13DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-23SEC
2026-10-01PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-01SEC
2026-10-018-KCurrent report2026-09-25SEC
2026-09-238-KCurrent report2026-09-23SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-148-KCurrent report2026-08-13SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-124Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-08-124Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-08-124Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-08-124Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-08-124Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-08-124Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-08-118-KCurrent report2026-08-11SEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-28SCHEDULE 13G/ASEC
2026-07-1310-K/A2025-12-31SEC
2026-06-168-KCurrent report2026-06-16SEC
2026-06-128-KCurrent report2026-06-12SEC
2026-05-218-KCurrent report2026-05-21SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-13SCHEDULE 13G/ASEC
2026-05-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-128-KCurrent report2026-05-12SEC
2026-04-30ARSAnnual report to security holders. 2025-12-31SEC
2026-04-30DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-16SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-12243.95K200
2025-110000

Institutional holders

Manager% owned
PERCEPTIVE ADVISORS LLC44.47%
ADAGE CAPITAL PARTNERS GP, L.L.C.5.67%
ADAR1 Capital Management, LLC5.43%
Alyeska Investment Group, L.P.5.22%
Sio Capital Management, LLC3.15%
GEODE CAPITAL MANAGEMENT, LLC2.98%
SILVERARC CAPITAL MANAGEMENT, LLC1.01%
Shaolin Capital Management LLC0.77%
VANGUARD CAPITAL MANAGEMENT LLC0.49%
Affinity Asset Advisors, LLC0.36%

Funds

Fund% owned
Fidelity Nasdaq Composite Index Fund2.59%
VANGUARD EXTENDED MARKET INDEX FUND0.41%
Fidelity Extended Market Index Fund0.23%
Fidelity Total Market Index Fund0.08%
VANGUARD TOTAL STOCK MARKET INDEX FUND0.08%
Fidelity Series Total Market Index Fund0.05%

OakChart. ADGM. Cached 15 minutes.